Table_1_Relative efficacy and safety of mesenchymal stem cells for osteoarthritis: a systematic review and meta-analysis of randomized controlled trials.docx

IntroductionThe aim of this meta-analysis was to evaluate the efficacy and safety of mesenchymal stem cells (MSCs) for the treatment of knee osteoarthritis (OA).
MethodsThe PubMed, Embase, Cochrane Central Register of Controlled Trials, Scopus and Web of Science databases were searched from inception to May 6, 2024 to identify randomized controlled trials that compared MSCs and placebo or other nonsurgical approaches for treating OA. Two investigators independently searched the literature and extracted data, and conventional meta-analyses were conducted with Review Manager 5.3. The outcomes included pain relief, functional improvement, and risk of adverse events (AEs).
ResultsA total of 18 articles were included. Overall, MSCs were superior to placebo in terms of relieving pain and improving function at the 12-month follow-up. However, the differences in treatment-related AEs were not significant.
ConclusionMSCs may relieving pain and improving function of OA. The limitations of this study include the high heterogeneity of the included studies. Additionally, the follow-up time in the included studies was relatively short, so more clinical trials are needed to predict the long-term efficacy and safety of MSCs.
Systematic review registrationhttps://doi.org/10.17605/OSF.IO/5BT6E, identifier CRD42022354824.

引言 本项荟萃分析旨在评估间充质干细胞（mesenchymal stem cells, MSCs）治疗膝骨关节炎（knee osteoarthritis, OA）的有效性与安全性。
研究方法 本研究检索了PubMed、Embase、Cochrane对照试验中心注册库、Scopus及Web of Science数据库，检索时限为建库至2024年5月6日，旨在筛选对比MSCs与安慰剂或其他非手术疗法治疗OA的随机对照试验。由2名研究者独立完成文献检索与数据提取工作，并采用Review Manager 5.3软件开展常规荟萃分析。研究结局指标包括疼痛缓解、功能改善及不良事件（adverse events, AEs）发生风险。
研究结果 最终共纳入18项文献。总体而言，在12个月随访时，MSCs在缓解疼痛与改善功能方面均优于安慰剂组；但两组治疗相关不良事件的差异无统计学意义。
研究结论 MSCs可缓解OA患者的疼痛并改善其关节功能。本研究存在一定局限性：纳入研究的异质性较高，且随访时间相对较短，因此仍需开展更多临床试验以明确MSCs的长期有效性与安全性。
系统评价注册信息 https://doi.org/10.17605/OSF.IO/5BT6E，标识符为CRD42022354824。